Abbott F. M. (2006), Intellectual property provisions of bilateral and regional trade agreements in light of US Federal law, Issue Paper n°12, International Centre for Trade and Sustainable Development/United Nations Conference on Trade and Development, Genève.
Ackiron E. (1991), « Patents for critical pharmaceuticals : the AZT case » Am J Law Med, 17 (1-2), pp. 145-80.
America's Health Insurance Plans (2019), The rise of orphan drugs, AHIP, Washington.
Amir T. et A.S. Kesselheim (2012), « Secondary patenting of branded pharmaceuticals : a case study of how patents on two HIV drugs could be extended for decades » Health Affairs, 31 (10), pp. 2286-2294.
Araujo de Mattos R., V. Terto, et R. Parker (2003), World Bank Strategies and the Response to AIDS in Brazil. Divulgação Em Saúde Para Debate.
Ardizzone K. (2020), Role of the U.S. federal government in the development of GS-5734/Remdesivir, KEI Briefing Note 2020 :1, Knowledge Ecology International, Washington.
Arno P., K. Bonuck et M. Davis (1995), « Rare diseases, drug development and AIDS : the impact of the Orphan Drug Act » The Milbank Quarterly, 73 (2), pp. 231–252.
Arrow K. (1962), “Economic Welfare and the Allocation of Resources for Invention” in R. Nelson (eds), The rate and direction of inventive activity : economic and social factors, Princeton, Princeton University Press, pp. 609-625.
Ashburn T.T. et K.B. Thor (2004), « Drug repositioning: identifying and developing new uses for existing drugs », Nat Rev Drug Discov, 3, pp. 673-684.
Banque Mondiale (2006), The economics of effective AIDS treatment, Evaluating policy options for Thailand, Washington D.C., The World Bank.
BBC Research (2016), Global Markets for Drug Repurposing. BCC Publishing, January.
Beall R. et R. Kuhn (2012), « Trends in compulsory licensing of pharmaceuticals since the Doha Declaration : a database analysis », PLoS Med, 9(1).
Beigel J. et al. (2020), « Remdesivir for the Treatment of Covid-19 — Final Report », N Engl J Med, 383, pp. 1813-1826.
Bird R.C. (2009), « Developing nations and the compulsory license : maximizing access to essential medicines while minimizing investment side effects » Journal of Law, Medicines & Ethics, 37, pp. 209-222.
Boulet P. et G. Velasquez (1999), Mondialisation et accès aux médicaments : les implications des Accords ADPIC/OMC, Genève, Organisation Mondiale de la Santé.
Boyer R. (2015), « L’essor du secteur de la santé annonce-t-il un modèle de développement anthropogénétique » Revue de la régulation, 1er semestre, 17.
Brown, A. (2020), « Estimating the cost of Covid-19 antiviral development » Evaluate, March, 12.
Busfield J. (2020), “Documenting the financialisation of the pharmaceutical industry” Social Science & Medicines, vol. 258, August, 113096.
Cassedy C. (2020), FDA states submission date of Gilead’s coronavirus treatment orphan status application is ‘confidential’, Knowlegde Ecology International, 25 March.
Chang J.H. (2002), Kicking away the ladder: development strategy in historical perspective, London, Anthem.
Chirac P. et E. Torreele (2006), “Global framework on essential health R&D” The Lancet, May, pp. 1560-1561.
Cimoli M., G. Dosi, K.E. Maskus, R.L. Okediji, J.H. Reichman et J.E. Stiglitz (2014), Intellectual property rights. Legal and economic challenges for development, Oxford, Oxford University Press.
Cohen W.M., R.R. Nelson, et J.P. Walsh (2000), Protecting their intellectual assets: appropriability conditions and why U.S. manufacturing firms patent (or not), NBER Working Papers 7552, National Bureau of Economic Research.
Congrès des Etats-Unis (1983), Orphan Drug Act 1983, U.S. Food and Drug Administration.
Correa C. (1999), Intellectual property rights and the use of compulsory licenses: options for developing countries, Working paper 5, South Centre.
Correa C. M. (2000), Intellectual property rights, the WTO and developing countries: the TRIPS Agreement and policy options, London, ZED-TWN.
Correa, C.M. (2020), Guidelines for the examination of pharmaceuticals patents : developing a public health perspective, International Centre for Trade and Sustainable Development, Genève.
Dalgalarrondo S. (2004), Sida : la course aux molécules, Paris, Editions de l’Ecole des hautes études en sciences sociales.
Danzon P.M., A.J. Epstein et S. Nicholson (2007), « Mergers and acquisitions in the pharmaceutical and biotech industries » Managerial and decision economics, 28, pp. 307-328.
Demsetz H. (1967), “Toward a Theory of Property Rights” American Economic Review, 57 (2), pp. 347–359.
Department of Health and Human Services (2001), The Orphan Drug Act : implementation and impact, May, Office of inspector general.
Desterbecq H. et B. Remiche (1996), « Les Brevets Pharmaceutiques dans les Accords du GATT: l’Enjeu? » Revue Internationale de Droit Economique, X (1), pp. 7-68.
Dieuaide P., B. Paulre et C. Vercellone (2003), Le capitalisme cognitif, Journée Matisse, 24 mars.
Eastman R.T., J.S. Roth, K.R. Brimacombe, A. Simeonov, M. Shen, S. Patnaik et M.D. Hall (2020), « Remdesivir : a review of its discovery and development leading to emergency use authorization for treatment of COVID-19 » ACS central science, 6 (5), pp. 672–683.
Epstein G.A. (2005), « Introduction: financialization of the world economy » in G.A. Epstein (eds), Financialization and the world economy, Cheltenham, Edward Elgar.
Fisher W.W. et C.P. Rigamonti (2005), « The South Africa AIDS controversy. A case study in patent law and policy », Harvard Law School, The Law and Business of Patents, February.
Flynn S., A. Hollis et M. Palmedo (2009), « An economic justification for open access to essential medicine patents in developing countries » Journal of Law, Medicines & Ethics, 37, pp. 184-210.
Gallagher K. P. (2005), Putting development first, London, Zed Books.
Gorry P. et D. Useche (2017), « Orphan drug designations as valuable intangible assets for IPO investors in pharma-biotech companies », NBER Working Paper 24021, National Bureau of Economic Research.
Gouvernement des Etats-Unis d’Amérique (2020), Proclamation on declaring a national emergency concerning the novel coronavirus disease (COVID-19) Outbreak, White House, 13 mars.
Government Pharmaceutical Organization (2015), Compulsory Licensing of Pharmaceutical Products, Bangkok, GPO, June.
Grabowsky H. G. (2002), « Patents, innovation and access to new pharmaceuticals » Journal of International Economic Law, 5 (4), pp. 849-60.
Guennif (2007), « Harmonisation globale des systèmes de brevet et impact locaux. Brevet et accès aux médicaments dans les pays en développement sous AADPIC et AADPIC plus » Economie et Institutions, 10, 1st semestre, pp. 251-284.
Guennif S. (2011), « Access to essential drugs in Thailand: intellectual property rights and other institutional matters affecting public health in a developing country » in K. Shadlen et al. (eds), Intellectual property, pharmaceuticals and public health : access to drugs in developing countries, Cheltenham, Edward Elgar Publishing, p. 286-310.
Guennif S. (2015), « La licence obligatoire : outil emblématique de la protection de la santé publique au Sud » Revue de la régulation, 1er Semestre.
Guennif S. et S. Ramani (2012), « Explaining divergence in catching-up in pharmaceuticals between India and Brazil using the national system innovation framework » Research Policy, Vol. 41, Issue 2, March, pp. 430-441.
Haffner M. (2016), « History of orphan drug regulation - United States and beyond » Clin Pharmacol Ther, 100 (4), pp. 342-343.
Harvey D. (2010), Le nouvel impérialisme, Paris, Les prairies ordinaires.
Hill, A., J. Wang, J. Levi, K. Heath et J. Fortunak (2020), « Minimum costs to manufacture new treatments for COVID-19 » Journal of virus eradication, 6(2), pp. 61–69.
Horowitz G. (2020), « Israel defies AbbVie IP to import generic drugs for COVID-19 », Law 360, March 19.
Institute for Clinical and Economic Review (2020), Alternative Pricing Models for Remdesivir and Other Potential Treatments for COVID-19, ICER, Boston.
Journal Officiel de la République Française (2020), Décret n° 2020-293 du 23 mars 2020 prescrivant les mesures générales nécessaires pour faire face à l'épidémie de covid-19 dans le cadre de l'état d'urgence sanitaire, JORF n°0072 du 24 mars 2020, texte n° 7.
Kapcynski A., C. Park et B. Sampat (2012), « Polymorphs and prodrugs and salts (Oh my!) : an empirical analysis of « secondary » pharmaceutical patents », PLoS ONE, 7(12).
Khor M. (2014), Compulsory license and « Government Use » to promote access to medicines : some examples, Penang, Third World Network.
Kingston W. (2001), “Innovation needs patents reform” Research Policy, 30, pp. 403–423.
Kiplin Guy K., R.S. DiPaola, F. Romanelli et R. Dutch (2020), « Rapid repurposing of drugs for COVID-19 », AAAS, 368(6493), pp. 829-830.
Knowledge Ecology International & Public Citizen (2020), Letter to Congress regarding Costa Rica proposal for WHO COVID-19 pool of rights in technology and data, Knowledge Ecology International, Washington.
Knowledge Ecology International (2020), English translation of Chile “Resolution for the granting of non-voluntary licenses referred to in article 51, n°2 of industrial property law n° 19.030 to facilitate access and availability of medicines and technologies for the prevention, treatment and cure of coronavirus covid-19, Knowledge Ecology International, Washington.
Krikorian G. (2013), « Conditions d’usage des licences obligatoires : l’action du gouvernement thaïlandais » in C. Possas et B. Larouze (eds), Accès aux antirétroviraux dans les pays du Sud. Propriété intellectuelle et politiques publiques, Paris, ANRS, pp. 51-67.
Lall S. (1974), « The international pharmaceutical industry and less-developed countries, with special reference to india” Oxford Bulletin of Economics and Statistics, 36(3), pp. 143-72.
Lall S. (2003), Indicators of the relative importance of IPRs in developing countries, Issue paper n°3, UNCTAD-ICTSD Project on IPRs and sustainable development, June.
Langedijk, J., A.K. Mantel-Teeuwisse, D.S. Slijkerman et M.H. Schutjens (2015), « Drug repositioning and repurposing : terminology and definitions in literature » Drug Discov Today, 20 (8), pp. 1027-1034.
Lazonick W., O. Tulum, M. Hopkins, M.E. Sakinç et K. Jacobson (2019), Financialization of the US pharmaceutical industry, The Academic-Industry Research Network, December.
Levin R., A. Klevorick, R. Nelson et S. Winter (1987), « Appropriating the returns from industrial research and development » Brookings papers on economic activity, 3, pp. 783-831.
Ling C. Y. (2006), « Malaysia’s experience in increasing access to antiretroviral drugs: exercising the ‘government use’ option », Intellectual Property Rights Series, Penang, Third World Network.
Love J. (2020), President and Minister of Health of Costa Rica ask WHO to create global pool for rights in COVID-19 related technologies, Knowledge Ecology International, Washington.
Luzzatto L, H.I. Hyry, A. Schieppati, E. Costa, S. Simoens, F. Schaefer, J.C.P. Roos, G. Merlini, H. Kääriäinen, S. Garattini, C.E. Hollak et G. Remuzzi (2018), « Outrageous prices of orphan drugs : a call for collaboration » Lancet, 392 (10149), pp. 791-794.
Machlup F. et E.T. Penrose (1950), « The patent controversy in the nineteenth century » The Journal of Economic History, vol. X, n°1, May, pp. 1-19.
Machlup F. (1958), An economic review of the patent system, Study of the Subcomittee on patents, trademarks, and copyrights of the Comitee on Judiciairy United States Senates, Eighty-fifth Congress, Second Session, Study n°15. Washington, United States Government printing office.
MacKelvey M., L. Orsenigo et F. Pammolli (2004), « Pharmaceuticals analyzed through the lens of a sectoral innovation system » in F. Malleba (eds), Sectoral systems of innovation. Concepts, issues and analyses of six majors sectors in Europe, Cambridge, Cambridge University Press, pp. 73-121.
Malerba F. (2002), « Sectoral systems of innovation and production » Research policy, 31 (2), pp. 247-264.
Mancini P. D., H. Kuchler et M. Peel (2020), « Remdesivir : the rise and fall of a COVID wonder drug », Financial Times, 24 November.
Mansfield E. (1986), « Patents and innovation : an empirical study » Management science, 2 (2), pp. 173-181.
Maskus K.E. et J.H. Reichman (2005), International public goods and transfer of technology under a globalized intellectual property regime, Cambridge, Cambridge University Press.
Matthews D. (2002), Globalising intellectual property rights: the TRIPS agreement, London, Routledge.
Médecins sans Frontières (2014), Pretoria : chronique d'un mauvais procès, Paris, MSF.
Medicines Patent Pool (2014), Le Medicines Patent Pool signe un accord de licence avec AbbVie pour des formulations pédiatriques à base de lopinavir et de ritonavir, MPP, 01 décembre 2014/Communiqué de presse.
Medicines Patent Pool (2015), Accord de licence ritonavir/lopinavir, MPP, 17 décembre/Communiqué de presse.
Mfuka C. (2002), « Accords ADPIC et brevets pharmaceutiques : le difficile accès des pays en développement aux médicaments antisida » Revue d'économie industrielle, 99, pp. 191-214.
Moatti J.P., B. Coriat, Y. Souteyrand, T. Barnett, J. Dumoulin et Y.A. Flory (2003), Economics of AIDS and access to HIV/AIDS care: issues and challenges. Paris, Edition de l’Agence Nationale de Recherches sur le Sida.
Monnier J. M. et C. Vercellone (2014), « Le capitalisme cognitif, nouvelle forme de capitalisme » Problèmes économiques, Hors-Série, La Documentation française, 5, pp. 117-220.
Montalban M. (2008), « Financiarisation et capitalisme cognitive. Interprétation institutionnaliste du cas de l’industrie pharmaceutique » in G. Colletis, et B. Paulré (eds), Les nouveaux horizons du capitalisme. Pouvoir, valeur, temps, Paris, Economica, pp.255-276.
Montalban M. et M.E. Sakinç (2013), “Financialization and productive models in the pharmaceutical industry” Industrial and Corporate Change, Volume 22, Issue 4, August, pp. 981–1030.
Moser P. (2013), « Patents and innovation : evidence from economic history » Journal of economic perspectives, 27, 1, pp. 23-44.
Moulier-Boutang Y. (2001), « Richesse, propriété, liberté et revenue dans le capitalisme cognitive » Multitures, n°5, pp. 17-36.
Moulier-Boutang Y. (2007), Le capitalisme cognitif, la nouvelle grande transformation, Paris, Edition Amsterdam.
Neuberger, A., N. Oraiopoulos et D.L. Drakerman (2019), « Renovation as innovation: is repurposing the future of drug discovery research” Drug Discovery Today, 24 (1), pp. 1-4.
Nik-Khah E. (2014), « Neoliberal pharmaceutical science and the Chicago School of Economics » Social studies of science, 44 (4), pp. 489-517.
Nosengo, N. (2016), « New tricks for old drugs » Nature, 534 (16), pp. 314-317.
Nunn A. (2009), The politics and history of AIDS treatment in Brazil, New-York, Springer.
ONUSIDA (2020), Synthèse rapport mondial 2020 — Agissons maintenant pour combattre les profondes inégalités et mettre fin aux pandémies, ONUSIDA, Rapport mondial, juillet.
Organisation Mondiale de la Santé (2020a), COVID-19 – Chronologie de l’action de l’OMS, OMS, 27 avril, Genève.
Organisation Mondiale de la Santé (2020b), WHO recommends against the use of remdesivir in COVID-19 patients, June, WHO, 20 novembre, Genève.
Organisation Mondiale de la Santé (2020c), WHO Director-General's opening remarks at the media briefing on COVID-19 - 18 March 2020, OMS, 18 mars, Genève.
Organisation Mondiale du Commerce (1994), Accord sur les aspects des droits de propriété intellectuelle qui touchent au commerce, 15 avril, Genève, OMC.
Organisation Mondiale du Commerce (2001), Déclaration ministérielle, Conférence ministérielle de l’OMC, Doha, 20 novembre 2001, Genève, OMC.
Organisation Mondiale du Commerce (2003), « Mise en œuvre du paragraphe 6 de la déclaration de Doha sur l'accord sur les ADPIC et la santé publique », Décision du Conseil général du 30 août 2003, Genève, OMC.
Pammolli F., L. Magazzini et M. Riccaboni (2012), « The productivity crisis in pharmaceutical R&D” Nat Rev Drug Discov, 10, pp. 428–38.
Penrose E. T. (1959), The Theory of the Growth of the Firm, New-York, John Wiley.
Perez-Casas C., C. Mace, D. Berman et J. Double (2001), Accessing ARVs: untangling the web of price reductions for developing countries, Campaign for access to essential drugs, September 20, Médecins sans Frontières.
Polamreddy P. et N. Gattu (2018), « The drug repurposing landscape from 2012 to 2017 : evolution, challenges, and possible solutions » Drug Discovery Today, 24 (3), pp. 789-796.
Possas de Albuquerque C. (2008), « Compulsory licensing in the real world : the case of ARV drugs in Brazil » in B. Coriat (eds), The political economy of HIV/AIDS in developing countries : TRIPS, public health systems and free Access, Cheltenham, Edward Elgar Publishing, pp. 150-169.
Public citizen (2020), The real story of remdesivir, Public citizen, Washington.
Pushpakom, S., F. Iorio, P.A. Eyers, K.J. Escott, S. Hopper, A. Wells, A. Doig, T. Guilliams, J. Latimer, C. McNamee, A. Norris, P. Sanseau, D. Cavalla et M. Pirmohamed (2019), « Drug repurposing : progress, challenges and recommendations » Nat Rev Drug Discov, 18 (1), pp. 41-58.
Rosenberg S. (2014), « Assessing the primacy of health over patent rights : a comparative study of the process that led to the use of compulsory licensing in Thailand and Brazil » Developing World Bioethics, 14 (2), pp. 83-89.
Rossi F. (2006), « Free trade agreements and TRIPS-plus measures » Int. J. Intellectual Property Management, 1 (1/2), pp. 150-172.
Roy V. (2017), The financialization of a cure : a political economy of biomedical innovation, pricing and public health, Thèse de doctorat en philosophie, University of Cambridge, King’s College.
Sampath P. G. (2005), Economic aspects of access to medicine after 2005 : product patent protection and emerging firms strategies in the Indian pharmaceutical industry, United Nations University, INTECH, May.
Scannell, J., A. Blanckley, H. Boldon et W. Warrington (2012), « Diagnosing the decline in pharmaceutical R&D efficiency » Nat Rev Drug Discov, 11, pp. 191–200.
Scherer F. M. (2007), Technological innovation and monopolization, Working Paper No. RWP07-043, .
Scherer F. M. (1998), The patent system and innovation in pharmaceuticals, Harvard University, December, John F Kennedy School of government, Harvard University.
Sell S.K. (2003), Private power, public law. The globalization of intellectual property rights, Cambridge, Cambridge University Press.
Sternitzke, C. (2014), « Drug repurposing and the prior art patents of competitors » Drug discovery Today, 19 (12), pp. 1841-1848.
Taylor P. (2020), « AbbVie won’t enforce patents for COVID-19 drug candidate Kaletra », Pharmaphorum, 25 March.
Thiru (2020), Israel issues compulsory license to allow the government to import generic versions of Kaletra, Knowledge Ecology International, 23 March.
Thoen E. (2020), « Covid-19 and the comeback of compulsory licensing », Medicines Law & Policy, 23 March.
US Food and Drug Administration (2020), Fact sheet for healthcare providers emergency use authorization (EUA) of veklury (remdesivir) for hospitalized pediatric patients weighing 3.5 kg to less than 40 kg or hospitalized pediatric patients less than 12 years of age weighing at least 3.5 kg, USFDA, Maryland.
Velasquez, G. (2015), Guidelines on patentability and access to medicines, Research Paper 61, South Centre, Genève.
Vercellone C. (2007), « La nouvelle articulation salaire, profit, rente dans le capitalisme cognitif » European Journal of Economic and Social Systems, 20 (1), pp. 45-64.
Vercellone C. (2008), « La thèse du capitalisme cognitif : une mise en perspective historique et théorique » in G. Colletis, et B. Paulré (eds), Les nouveaux horizons du capitalisme. Pouvoir, valeur, temps, Paris, Economica, pp.71-95.
Viegas Neves Da Silva F., R. Hallal et A. Guimaraes (2012), « Compulsory license and access to medicines: economic savings of Efavirenz in Brazil », the XIX International AIDS Conference, Washington, July.
Wong H. (2020), « The case for compulsory licensing during COVID-19 » Journal of global health, 10(1), 010358.